Tags: merck | verona | lung | therapy

Merck Shells Out $10B for Lung Therapy Firm Verona

Merck Shells Out $10B for Lung Therapy Firm Verona
(AP)

Wednesday, 09 July 2025 07:12 AM EDT

Merck will buy UK-based Verona Pharma for about $10 billion, the companies said Wednesday, strengthening the U.S. firm's respiratory treatment portfolio in a bid to diversify its revenue source beyond its blockbuster cancer drug.

Merck has been leaning on its aging cancer immunotherapy Keytruda, the world's top-selling prescription medicine, which generated nearly $30 billion in sales in 2024, but faces patent expiries starting in 2028.

In response, the company has ramped up deal-making to broaden its revenue base. The latest deal is Merck's largest since its $10.8 billion buyout of Prometheus Biosciences in 2023.

It builds on the company's portfolio of chronic lung disease treatments, including recently approved Winrevair and Enflonsia.

Merck will pay $107 per American depository share for London-based Verona, a premium of 23% to Verona's last closing price on the Nasdaq. Verona's U.S.-listed shares jumped 20% in premarket trading.

Verona, which is also listed in Frankfurt, rose into prominence with the approval of its inhalable, non-steroid treatment Ohtuvayre for patients with chronic obstructive pulmonary disease, also known as "smoker's lung," a common lung disease affecting nearly 16 million Americans.

Ohtuvayre was approved last year and brought in annual sales of $42.3 million. Jefferies analysts expect the drug to have peak annual sales of more than $3 billion.

The Financial Times first reported that Merck was nearing a deal to acquire Verona. Last month, FT reported that Merck held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion.

© 2025 Thomson/Reuters. All rights reserved.


StreetTalk
Merck will buy UK-based Verona Pharma for about $10 billion, the companies said Wednesday, strengthening the U.S. firm's respiratory treatment portfolio in a bid to diversify its revenue source beyond its blockbuster cancer drug.
merck, verona, lung, therapy
243
2025-12-09
Wednesday, 09 July 2025 07:12 AM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Get Newsmax Text Alerts
TOP

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved